Possible participation of receptor for advanced glycation end products (RAGE) in the origin of cancer stem cells in diabetic patients with colon cancer

Medical Hypotheses

Volumn 80, Issue 5, 2013, Pages 620-623

  Hu, Xiang ^a   Cheng, Yong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN S 100; TRANSFORMING GROWTH FACTOR;

ARTICLE; CANCER GROWTH; CANCER RISK; CANCER STEM CELL; CARCINOGENICITY; CELL PROLIFERATION; COLON CANCER; COLORECTAL ADENOMA; DIABETES MELLITUS; DIABETIC PATIENT; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; IMMUNOHISTOCHEMISTRY; PATHOPHYSIOLOGY; PRECANCER; SIDE POPULATION CELL; TUMOR MICROENVIRONMENT;

COLONIC NEOPLASMS; DIABETES COMPLICATIONS; HUMANS; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; RECEPTORS, IMMUNOLOGIC;

EID: 84875577332     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.02.004     Document Type: Article

References (24)

1. International Diabetes Federation The diabetes atlas 2009, International Diabetes Federation, Brussels. 4th ed.
2. Larsson S.C., Giovannucci E., Wolk A. Diabetes and colorectal cancer incidence in the cohort of Swedish men. Diabetes Care 2005, 28(7):1805-1807.
3. Hu F.B., Manson J.E., Liu S., et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 1999, 91(6):542-547.
4. Rojas A., Figueroa H., Morales E. Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. Carcinogenesis 2010, 31(3):334-341.
5. Rakoff-Nahoum S., Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009, 9(1):57-63.
6. Hiwatashi K., Ueno S., Kubo F., et al. Relevance of apoptosis and tolerance to hypoxic stress in cells transfected with receptor for advanced glycation end products (RAGE). Anticancer Res 2009, 29(4):1287-1294.
7. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001, 108(7):949-955.
8. Lohwasser C., Neureiter D., Weigle B., Kirchner T., Schuppan D. The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha. J Invest Dermatol 2006, 126(2):291-299.
9. He M., Kubo H., Ishizawa K., et al. The role of the receptor for advanced glycation end-products in lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2007, 293(6):L1427-1436.
10. Jung D.H., Kim Y.S., Kim J.S. KIOM-79 prevents S100b-induced TGF-beta1 and fibronectin expression in mouse mesangial cells. J Ethnopharmacol 2009, 125(3):374-379.
11. Stein U., Arlt F., Walther W., et al. The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology 2006, 131(5):1486-1500.
12. Moustakas A., Heldin C.H. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 2007, 98(10):1512-1520.
13. Morel A.P., Lievre M., Thomas C., et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008, 3(8):e2888.
14. Machida K., Chen C.L., Liu J.C., et al. Cancer stem cells generated by alcohol, diabetes, and hepatitis C virus. J Gastroenterol Hepatol 2012, 27(Suppl. 2):19-22.
15. Heijmans J., Buller N.V., Hoff E., et al. Rage signalling promotes intestinal tumourigenesis. Oncogene 2012, http://dx.doi.org/10.1038/onc.2012.119.
16. Sasahira T., Akama Y., Fujii K., Kuniyasu H. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch 2005, 446(4):411-415.
17. Kuniyasu H., Chihara Y., Takahashi T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 2003, 10(2):445-448.
18. Palanisamy N., Kannappan S., Anuradha C.V. Genistein modulates NF-kappaB-associated renal inflammation, fibrosis and podocyte abnormalities in fructose-fed rats. Eur J Pharmacol 2011, 667(1-3):355-364.
19. Yamagishi S., Inagaki Y., Okamoto T., et al. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Kidney Int 2003, 63(2):464-473.
20. Palumbo R., Bianchi M.E. High mobility group box 1 protein, a cue for stem cell recruitment. Biochem Pharmacol 2004, 68(6):1165-1170.
21. Lo J.F., Yu C.C., Chiou S.H., et al. The epithelial-mesenchymal transition mediator S100A4 maintains cancer-initiating cells in head and neck cancers. Cancer Res 2011, 71(5):1912-1923.
22. Harris M.A., Yang H., Low B.E., et al. Cancer stem cells are enriched in the side population cells in a mouse model of glioma. Cancer Res 2008, 68(24):10051-10059.
23. Song J.S., Kang C.M., Park C.K., et al. Inhibitory effect of receptor for advanced glycation end products (RAGE) on the TGF-β-induced alveolar epithelial to mesenchymal transition. Exp Mol Med 2011, 43(9):517-524.
24. Buckley S.T., Medina C., Kasper M., Ehrhardt C. Interplay between RAGE, CD44, and focal adhesion molecules in epithelial-mesenchymal transition of alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 2011, 300(4):L548-L559.